Plasmodium falciparum liver-stage antigen 3 (LSA-3) (PfLSA-3)

Plasmodium falciparum liver-stage antigen 3 (PfLSA-3) is a large, 200 kDa protein expressed on the surface of sporozoites and within infected hepatocytes during the pre-erythrocytic stage of malaria (Daubersies et al., 2000, Nature Medicine). Human B-cell receptors (BCRs) and antibodies specific for LSA-3 epitopes are critical for neutralizing the parasite and preventing the establishment of a blood-stage infection (Brahimi et al., 1993, Journal of Immunology). LSA-3 is highly conserved across different parasite isolates, which makes it a primary candidate for the development of broad-spectrum malaria vaccines (Perlaza et al., 2001, Clinical and Experimental Immunology). The interaction between LSA-3 and human BCRs is studied to identify potent neutralizing epitopes, facilitating the design of immunogens that can elicit protective antibody responses (Sacci et al., 2002, Vaccine). Therapeutic strategies include the use of recombinant protein vaccines, such as LSA3-729, and the potential application of monoclonal antibodies for passive immunization. Despite its potential, challenges remain in achieving high-affinity, long-lasting immune memory against LSA-3 in diverse human populations.

Other names

LSA-3Liver-stage antigen 3PfLSA3Antigen LSA3Human B-cell receptors specific for LSA-3

Inhibition of sporozoite invasion of hepatocytes and opsonization of infected cells by specific antibodies.